{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=36", "query": { "condition": "Dose Finding Study", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 868, "total_pages": 87, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T03:56:13.081Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00628251", "title": "Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "AZD2281", "type": "DRUG" }, { "name": "Liposomal Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 97, "start_date": "2008-07-30", "completion_date": "2018-09-19", "has_results": true, "last_update_posted_date": "2019-12-05", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Boca Raton, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00628251" }, { "nct_id": "NCT04368728", "title": "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection", "COVID-19" ], "interventions": [ { "name": "BNT162b1", "type": "BIOLOGICAL" }, { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "BNT162b2SA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 46969, "start_date": "2020-04-29", "completion_date": "2023-02-10", "has_results": true, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 154, "location_summary": "Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04368728" }, { "nct_id": "NCT05071612", "title": "Parallel Arm Trial of AD109 and AD504 In Patients With OSA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "OSA - Obstructive Sleep Apnea" ], "interventions": [ { "name": "AD109", "type": "DRUG" }, { "name": "AD504", "type": "DRUG" }, { "name": "Atomoxetine Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apnimed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 294, "start_date": "2021-11-29", "completion_date": "2022-08-03", "has_results": true, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 25, "location_summary": "Los Angeles, California • San Diego, California • Santa Ana, California + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Brandon", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05071612" }, { "nct_id": "NCT00692159", "title": "Study of TRC102 in Combination With Pemetrexed in Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "TRC102 + pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tracon Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2008-06", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2010-09-10", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Cleveland, Ohio", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00692159" }, { "nct_id": "NCT00758524", "title": "A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Essential Hypertension" ], "interventions": [ { "name": "LCI699", "type": "DRUG" }, { "name": "Eplerenone", "type": "DRUG" }, { "name": "LCI699-matching Placebo", "type": "DRUG" }, { "name": "Eplerenone-matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 628, "start_date": "2008-09-11", "completion_date": "2009-07-02", "has_results": true, "last_update_posted_date": "2021-07-06", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00758524" }, { "nct_id": "NCT00497809", "title": "Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Neutropenia" ], "interventions": [ { "name": "AVI-014 versus Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AviGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 189, "start_date": "2007-08", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2011-05-03", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 14, "location_summary": "Anaheim, California • Greenbrae, California • Los Angeles, California + 11 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "West Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00497809" }, { "nct_id": "NCT04381052", "title": "Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Clazakizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-05-18", "completion_date": "2021-04-01", "has_results": true, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04381052" }, { "nct_id": "NCT05145816", "title": "Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AL Amyloidosis", "Amyloidosis" ], "interventions": [ { "name": "Belantamab mafodotin 2.5 mg/kg (8 weeks)", "type": "DRUG" }, { "name": "Belantamab mafodotin 1.9 mg/kg (8 weeks)", "type": "DRUG" }, { "name": "Belantamab mafodotin 1.4 mg/kg (12 weeks)", "type": "DRUG" }, { "name": "Belantamab mafodotin 1.9 mg/kg (12 weeks)", "type": "DRUG" }, { "name": "Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages", "type": "DRUG" }, { "name": "Belantamab mafodotin 1.0 mg/kg (12 weeks)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2024-02-15", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 3, "location_summary": "Nashville, Tennessee • Dallas, Texas • Salt Lake City, Utah", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05145816" }, { "nct_id": "NCT01386385", "title": "Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Adenocarcinoma", "Lung Adenocarcinoma, Mixed Subtype", "Lung Large Cell Carcinoma", "Lung Squamous Cell Carcinoma", "Minimally Invasive Lung Adenocarcinoma", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2011-06-20", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 232, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01386385" }, { "nct_id": "NCT01313117", "title": "Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Peripheral Neuropathy" ], "interventions": [ { "name": "Alpha lipoic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2012-02", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2014-10-02", "last_synced_at": "2026-10-26T03:56:13.081Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313117" } ] }